Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age

被引:67
|
作者
Beaber, Elisabeth F. [1 ,2 ,3 ]
Buist, Diana S. M. [1 ,3 ]
Barlow, William E. [4 ]
Malone, Kathleen E. [2 ,3 ]
Reed, Susan D. [1 ,2 ,3 ,5 ]
Li, Christopher I. [2 ,3 ]
机构
[1] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA
[2] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA
关键词
YOUNG-WOMEN; UNITED-STATES; EPITHELIAL PROLIFERATION; HORMONAL CONTRACEPTIVES; ESTROGEN-RECEPTOR; HISTORIES; PROGESTINS; COHORT; TRENDS;
D O I
10.1158/0008-5472.CAN-13-3400
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies of oral contraceptives and breast cancer indicate that recent use slightly increases risk, but most studies relied on self-reported use and did not examine contemporary oral contraceptive formulations. This nested case-control study was among female enrollees in a large U. S. integrated health care delivery system. Cases were 1,102 women ages 20 to 49 years diagnosed with invasive breast cancer from 1990 to 2009. Controls were randomly sampled from enrollment records (n = 21,952) and matched to cases on age, year, enrollment length, and medical chart availability. Detailed oral contraceptive use information was ascertained from electronic pharmacy records and analyzed using conditional logistic regression, ORs, and 95% confidence intervals (CI). Recent oral contraceptive use (within the prior year) was associated with an increased breast cancer risk (OR, 1.5; 95% CI, 1.3-1.9) relative to never or former OC use. The association was stronger for estrogen receptor-positive (ER+; OR, 1.7; 95% CI, 1.3-2.1) than estrogen receptor-negative (ER-) disease (OR, 1.2, 95% CI, 0.8-1.8), although not statistically significantly different (P = 0.15). Recent use of oral contraceptives involving high-dose estrogen (OR, 2.7; 95% CI, 1.1-6.2), ethynodiol diacetate (OR, 2.6; 95% CI, 1.4-4.7), or triphasic dosing with an average of 0.75 mg of norethindrone (OR, 3.1; 95% CI, 1.9-5.1; P-heterogeneity compared with using other oral contraceptives = 0.004) was associated with particularly elevated risks, whereas other types, including low-dose estrogen oral contraceptives, were not (OR, 1.0; 95% CI, 0.6-1.7). Our results suggest that recent use of contemporary oral contraceptives is associated with an increased breast cancer risk, which may vary by formulation. If confirmed, consideration of the breast cancer risk associated with different oral contraceptive types could impact discussions weighing recognized health benefits and potential risks. (C)2014 AACR.
引用
收藏
页码:4078 / 4089
页数:12
相关论文
共 50 条
  • [21] Oral contraceptive (OC) use and risk of breast cancer
    H Tómasson
    British Journal of Cancer, 1997, 76 : 416 - 416
  • [22] ORAL-CONTRACEPTIVE USE AND BREAST-CANCER RISK IN YOUNG-WOMEN
    CHILVERS, C
    LANCET, 1989, 1 (8645): : 973 - 982
  • [23] Oral contraceptive use in women at increased risk of breast/ovarian cancer: knowledge and attitudes
    Bui, Kim Tam
    Wakefield, Claire E.
    Kasparian, Nadine A.
    Tyler, Janet
    Abbott, Jason
    Tucker, Kathy
    PSYCHO-ONCOLOGY, 2013, 22 (01) : 228 - 232
  • [24] ORAL-CONTRACEPTIVE USE AND THE RISK OF BREAST-CANCER IN YOUNG-WOMEN
    RUBIN, G
    WEBSTER, L
    STADEL, B
    WINGO, P
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 122 (03) : 516 - 516
  • [25] ORAL-CONTRACEPTIVE USE AND THE RISK OF BREAST-CANCER IN YOUNG-WOMEN
    RUBIN, GL
    WEBSTER, LA
    STADEL, B
    WINGO, PA
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1985, 8 (03): : A88 - A88
  • [27] Contraceptive use in women under 20 years of age: A study in Iran
    Shahpoorian, F.
    Kashanian, M.
    Shakhan, Z.
    Sheikhansari, N.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 34 (07) : 625 - 629
  • [28] Oral contraceptive use and risk of diabetes among Chinese women
    Rosenthal, AD
    Shu, XO
    Jin, F
    Yang, G
    Elasy, TA
    Li, Q
    Xu, HX
    Gao, YT
    Zheng, W
    CONTRACEPTION, 2004, 69 (03) : 251 - 257
  • [29] Oral Contraceptive Use and Survival in Women with Invasive Breast Cancer
    Lu, Yani
    Ma, Huiyan
    Malone, Kathleen E.
    Norman, Sandra A.
    Sullivan-Halley, Jane
    Strom, Brian L.
    Simon, Michael S.
    Marchbanks, Polly A.
    McDonald, Jill A.
    West, Dee W.
    Henderson, Katherine D.
    Deapen, Dennis
    Ursin, Giske
    Bernstein, Leslie
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (07) : 1391 - 1397
  • [30] ORAL-CONTRACEPTIVE USE AND THE RISK OF BREAST-CANCER
    不详
    NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (07): : 405 - 411